HOME >> MEDICINE >> NEWS
NIAID launches first Phase II trial of a 'global' HIV/AIDS vaccine

A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants at sites in Africa, North America, South America and the Caribbean to test the safety and immune response to the vaccine.

The experimental vaccine was developed by scientists at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC) and is being studied in the HIV Vaccine Trials Network (HVTN), a clinical research collaboration funded by NIAID's Division of AIDS (DAIDS).

"This trial marks an important step in the advancement toward an AIDS vaccine. The rapid development of this candidate vaccine--less than five years since the launch of the VRC--underscores our commitment to hasten the day when we have an effective AIDS vaccine," says NIAID Director Anthony S. Fauci, M.D.

The unique vaccine combines synthetically modified elements of four HIV genes found in subtypes A, B and C of the virus--the subtypes commonly found in Africa, the Americas, Europe and parts of Asia. These subtypes represent about 85 percent of HIV infections worldwide.

"This is the first Phase II study of a vaccine candidate that is broadly relevant to the global AIDS pandemic because it combines components of HIV strains found throughout the world," says VRC Director Gary Nabel, M.D., Ph.D. "We look forward to working with our partners in the United States and abroad as we take this vaccine into the next phase of clinical evaluation."

The trial, known as HVTN 204, is being coordinated with two other planned clinical studies, an unprecedented collaboration among researchers in three clinical trial networks and NIAID. The International AIDS Vaccine Initiative plans to conduct a Phase I study of the VRC vaccine at sites in Kenya and Rwand
'"/>

Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
11-Oct-2005


Page: 1 2 3 4

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. NIAID awards $4 million to develop anti-radiation treatments
5. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
6. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
7. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
8. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
9. NIAID media availability: Understanding influenza infection
10. NIAID researchers show how promising TB drug works
11. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... February 19, 2019 , ... ... Innovative Techniques to Improve Inspections, **Presented by FDAnews and Learning Plus**, Mar. 26-27, ... Advanced Root Cause Analysis CAPA Investigationsends on Feb. 26. , The greatest ...
(Date:2/19/2019)... ... February 19, 2019 , ... The American Case Management Association ... and launched by the Center for Case Management in 2000, the purpose of ... supervisors and leaders. , “I created the CMAC credential because leaders in ...
(Date:2/19/2019)... ... February 19, 2019 , ... Renowned eye surgeon and founder ... first ever supplement to help support Keratoconus cornea health. Keratoconus is a ... supplement, KC Defense, includes specific amounts Copper (Cu) and Selenium (Se), elements that ...
(Date:2/19/2019)... ... , ... WEDI , the nation’s leading nonprofit authority on the use ... to the U.S. Department of Health and Human Services (HHS), today issued the following ... following the release last week at the HIMSS Global Conference and Exhibition by the ...
(Date:2/19/2019)... Mass. (PRWEB) , ... February 19, 2019 , ... ... the impact of weight stigma in pregnant and postpartum women, a team led ... during pregnancy and early postpartum often show increased depressive symptoms, greater weight gain ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... ... most-esteemed living artists, fine-arts painter Rick Phillips is doing what he wants to ... “You get that feeling in your belly, this is what I really want to do. ... former commercial artist a serenity and fulfilment he hopes to bring to those recovering from ...
(Date:2/19/2019)... ... February 19, 2019 , ... Leading ... receive medical-grade manicure and pedicure services with their newest venture, Medicure Hand and ... treatments for patients suffering from Diabetes and Arthritis, and those undergoing Chemotherapy. , ...
(Date:2/19/2019)... ... 19, 2019 , ... Job Research Foundation , which ... community with additional opportunities to further research into the rare immunodeficiency disorder, has ... Foundation’s Scientific Advisory Board and the addition of Dr. Andrew R. Gennery to ...
Breaking Medicine Technology:
Cached News: